Almirall and Sun Pharma in $50 million European license deal for psoriasis drug tildrakizumab

28 July 2016

India's Sun Pharmaceutical (BSE: 524715) and Spain’s Almirall (ALM: MC) have announced a licensing agreement on the development and commercialization of tildrakizumab for psoriasis in Europe.

Tildrakizumab is an investigational IL-23p19 inhibitor currently being trialled in patients with moderate-to-severe plaque psoriasis, and Phase III studies of the treatment have just been completed.

Almirall will pay Sun Pharma an initial upfront of $50 million as part of the deal, and the Mumbai-based company will be eligible to receive development and regulatory milestone payments as well as sales milestone payments and royalties on net sales.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK